Current and emerging strategies for the management of sarcoidosis

@article{White2007CurrentAE,
  title={Current and emerging strategies for the management of sarcoidosis},
  author={Eric S White and Joseph P Lynch Iii},
  journal={Expert Opinion on Pharmacotherapy},
  year={2007},
  volume={8},
  pages={1293 - 1311}
}
Sarcoidosis is a systemic inflammatory disorder of unknown etiology. Although any organ may be involved, the lungs are most frequently affected. The clinical course of the disease is highly variable, with up to two-thirds of untreated patients experiencing spontaneous remission within 12 – 24 months of onset of symptoms. When therapy is required, corticosteroids are considered standard, but studies demonstrating their ability to modify the long-term outcome in this disease are lacking. Often… Expand
Cutaneous sarcoidosis: current therapeutic modalities
TLDR
Cutaneous sarcoidosis is a chronic, inflammatory, granulomatous disorder of unknown etiology that can be recalcitrant to many therapeutic modalities and is dependent on the extent of cutaneous involvement and the degree of systemic manifestations. Expand
Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease.
TLDR
The current knowledge and advances in the epidemiology, etiology, pathogenesis, and genetics of sarcoidosis are reviewed, the heterogeneous manifestations of cutaneous sarcoIDosis are discussed, and a guide for treatment is provided. Expand
The puzzling clinical spectrum and course of juvenile sarcoidosis
TLDR
Sarcoidosis in childhood is recognized as a systemic disease affecting various organs and having diverse clinical course depending on the age of onset, and new, novel therapies may change the outcome of the disease. Expand
Childhood sarcoidosis: A rare but fascinating disorder
TLDR
The current therapy of choice for sarcoidosis in children with multisystem involvement is oral corticosteroids, and Methotrexate given orally in low doses has been effective, safe and steroid sparing in some patients. Expand
An unusual case of childhood sarcoidosis: Un caso clínico infrecuente.
TLDR
The aim of this report is to present an unusual case of childhood sarcoidosis with stage III lung involvement without extrapulmonary organ involvement in a 7-year-old girl with complaints of malaise, fatigue, weight loss and dyspnea. Expand
Clinical cases presentation
TLDR
An unusual case of childhood sarcoidosis with stage III lung involvement without any extrapulmonary organ involvement of a 7-year-old girl with complaints of malaise, fatigue, weight loss and dyspnea is presented. Expand
Clinical Manifestations of Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown etiology that is characterized from the point of view of pathology of the presence of noncaseating granulomas in affected organs. TypicallyExpand
Sarcoidosis and the Th 1 chemokine MIG
Sarcoidosis is a systemic inflammatory disease, affecting any organ, and that can be discovered by accident in approximately 5% of cases. The most common symptoms are fatigue, weight loss, lack ofExpand
An Unusual Entity of Sarcoidosis: Acute Parotitis
TLDR
A rare case of sarcoidosis stage III diagnosed in a child patient with acute parotitis is presented and the relevant literature is reviewed. Expand
Hypercalcemia after transplant nephrectomy in a hemodialysis patient: a case report
TLDR
This case demonstrates that withdrawal of immunosuppressive drugs sometimes unmasks sarcoidosis, and should be considered as differential diagnosis even in hemodialysis patients, in whom other reasons for hypercalcemia are much more common. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 185 REFERENCES
Sarcoidosis: is therapy effective?
TLDR
The pharmacologic agents used to treat sarcoidosis, toxicities associated with treatment, and appropriate use and monitoring of these therapeutic modalities are reviewed. Expand
Sarcoidosis: clinical update.
  • U. Costabel
  • Medicine
  • The European respiratory journal. Supplement
  • 2001
TLDR
For asymptomatic pulmonary sarcoidosis, a watch and wait approach is appropriate; treatment should mainly be considered if symptoms develop or lung function deteriorates, although there are indications of valuable alternatives. Expand
Outcome of sarcoidosis.
TLDR
This article reviews the outcomes from the point of view of relevant clinical phenotypes, the natural disease course, the effects of treatment, and the efficacy of several novel therapeutic drugs in treating sarcoidosis. Expand
Diagnosis and treatment of hepatic sarcoidosis
TLDR
Treatment for hepatic sarcoidosis is targeted toward alleviation of symptoms but has no curative potential at this time, and focus should be on discovering the etiology of the disease to target therapy at prevention, not cure. Expand
Refractory sarcoidosis responding to infliximab.
TLDR
A case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy is reported, and oculocutaneous Sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab. Expand
Cyclosporine and chronic sarcoidosis.
TLDR
While corticosteroids remain the mainstay of sarcoid therapy, when these drugs have not been successful for the skin manifestations of the disease, a trial of cyclosporine may be justified. Expand
Natural history of hepatic sarcoidosis and its response to treatment
TLDR
Sarcoidosis can cause end-stage chronic liver disease, which is often unrecognized until examination of the explanted liver, and response to conventional immunosuppression is variable and unpredictable. Expand
Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil
TLDR
The report of a child with severe renal failure secondary to renal limited sarcoidosis who was successfully treated with corticosteroid induction therapy and has been in sustained remission for over a year with mycophenolate mofetil monotherapy. Expand
Low-dose methotrexate: an effective corticosteroid-sparing agent in the musculoskeletal manifestations of sarcoidosis.
TLDR
Low-dose oral methotrexate appears to be an efficient, safe and corticosteroid-sparing therapeutic agent for the treatment of recalcitrant musculoskeletal manifestations of sarcoidosis. Expand
Treatment of Complicated Sarcoidosis with Infliximab AntiTumor Necrosis Factor- Therapy
TLDR
An unusual case of sarcoidosis, manifested by severe protein-losing enteropathy and proximal myopathy, in which the patient responded dramatically to infliximab therapy, which was complicated by the development of hypercoagulability associated with anticardiolipin antibodies. Expand
...
1
2
3
4
5
...